Mabwell: Meiwei Biology voluntarily discloses the announcement of the Phase III clinical study of 9MW2821 combined with PD-1 monoclonal antibody for first-line treatment of urinary tract urothelial carcinoma, which has obtained the approval of the CDE.

SZSI · Aug 26

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

迈威生物：迈威生物自愿披露关于9MW2821联合PD-1单抗一线治疗尿路上皮癌的Ⅲ期临床研究获得CDE同意的公告

Mabwell: Meiwei Biology voluntarily discloses the announcement of the Phase III clinical study of 9MW2821 combined with PD-1 monoclonal antibody for first-line treatment of urinary tract urothelial carcinoma, which has obtained the approval of the CDE.

Risk Disclaimer

Statement